480 related articles for article (PubMed ID: 16298013)
1. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study.
Chen CH; Lee CM; Hung CH; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
Liver Int; 2007 Aug; 27(6):806-15. PubMed ID: 17617124
[TBL] [Abstract][Full Text] [Related]
3. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
Cho SW; Hahm KB; Kim JH
Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
[TBL] [Abstract][Full Text] [Related]
4. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
[TBL] [Abstract][Full Text] [Related]
5. [The prevalence and clinical significance of precore and core promoter mutations in Korean patients with chronic hepatitis B virus infection].
Kim HJ; Yoo BC
Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):149-56. PubMed ID: 12499800
[TBL] [Abstract][Full Text] [Related]
6. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
[TBL] [Abstract][Full Text] [Related]
7. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
8. HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B.
Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Takagi K; Kumada H
J Med Virol; 2003 Jul; 70(3):355-60. PubMed ID: 12766997
[TBL] [Abstract][Full Text] [Related]
9. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
Lok AS; Hussain M; Cursano C; Margotti M; Gramenzi A; Grazi GL; Jovine E; Benardi M; Andreone P
Hepatology; 2000 Nov; 32(5):1145-53. PubMed ID: 11050068
[TBL] [Abstract][Full Text] [Related]
10. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
11. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
[TBL] [Abstract][Full Text] [Related]
12. Determinants for sustained HBeAg response to lamivudine therapy.
Chien RN; Yeh CT; Tsai SL; Chu CM; Liaw YF
Hepatology; 2003 Nov; 38(5):1267-73. PubMed ID: 14578866
[TBL] [Abstract][Full Text] [Related]
13. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy.
Lin CL; Liao LY; Wang CS; Chen PJ; Lai MY; Chen DS; Kao JH
Liver Int; 2004 Feb; 24(1):9-15. PubMed ID: 15101995
[TBL] [Abstract][Full Text] [Related]
14. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
[TBL] [Abstract][Full Text] [Related]
15. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.
Watanabe K; Takahashi T; Takahashi S; Okoshi S; Ichida T; Aoyagi Y
J Gastroenterol Hepatol; 2005 Mar; 20(3):441-9. PubMed ID: 15740490
[TBL] [Abstract][Full Text] [Related]
17. Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy.
Buti M; Jardi R; Rodriguez-Frias F; Valdes A; Schaper M; Esteban R; Guardia J
Aliment Pharmacol Ther; 2005 Jun; 21(11):1349-56. PubMed ID: 15932365
[TBL] [Abstract][Full Text] [Related]
18. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
Marrone A; Zampino R; Karayannis P; Cirillo G; Cesaro G; Guerrera B; Ricciotti R; del Giudice EM; Utili R; Adinolfi LE; Ruggiero G
Aliment Pharmacol Ther; 2005 Oct; 22(8):707-14. PubMed ID: 16197491
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus genotypes and precore/core-promoter mutations in Tunisian patients with chronic hepatitis B virus infection.
Ayed K; Gorgi Y; Ayed-Jendoubi S; Aouadi H; Sfar I; Najjar T; Ben Abdallah T
J Infect; 2007 Mar; 54(3):291-7. PubMed ID: 16911832
[TBL] [Abstract][Full Text] [Related]
20. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]